Briakinumab, chemically identified as 339308-60-0, represents a distinct biologic therapy exhibiting significant application in the management of moderate to severe plaque condition and symptomatic alopecia areata . This protein selectively blocks the IL-12 and interleukin pathways, crucial elements in the inflammatory process underlying these diseases. Preclinical and clinical results suggest a marked improvement with encouraging sustained outcomes , particularly in patients who have not responded to other systemic treatments . Further study continues to explore its full clinical application and identify optimal patient populations for personalized care strategies.
Study 695: Exploring the Research Behind Briakinumab's Function
J 695, a important paper, examines the complex cellular basis of briakinumab's therapeutic efficacy . The findings emphasize how this interleukin-12/23 antagonist specifically binds to J 695 the IL-12 receptor beta 1 subunit, interfering with subsequent pathways that promote inflammation. Additionally, the study clarifies the role of specific amino acids within the molecule accountable for the remarkable attachment affinity observed. Ultimately , J 695 provides a substantial perspective into the precise biological mechanisms governing briakinumab's mode of operation .
- Example analyses on subject reaction
- Exact figures depicting the association event
- Comparison of briakinumab with alternative pharmaceutical agents
BSF415977: Exploring the Development History of Briakinumab
A study into BSF415977, now known as briakinumab, reveals a lengthy evolution marked by crucial milestones and challenging hurdles. Initially , the compound emerged from research at researchers, focusing on blocking interleukin-12 and interleukin-23, cytokines linked in the development of autoimmune conditions .
Preliminary clinical tests showed potential in treating psoriasis, prompting further exploration and advancement . However, challenges arose concerning risk and action, requiring refinements to the patient program .
- Before that time, the progress faced considerable setbacks.
- Subsequent review focused on determining biomarkers indicating patient benefit.
- Finally , briakinumab secured clearance for treating moderate-to-severe plaque psoriasis in certain patients.
Briakinumab: Latest Investigations and Clinical Study Progress
New research into the drug persist to assess its benefit in addressing significant psoriasis and associated inflammatory illnesses. Several clinical trials are presently in progress, directed on exploring alternative usage approaches, such as joint therapy with various medications and determining long-term well-being and influence on personal experiences. Initial evidence from these studies suggests possible benefits in specific patient populations, more evaluation is required to fully understand the complete clinical profile. Remarkably, researchers are also studying the medication's potential in various immunological conditions.
Chemical Profile and Properties of Briakinumab
Briakinumab, often identified by its CAS number, registration number, chemical identifier 339308-60-0, is a human, monoclonal, recombinant antibody designed, engineered, developed for the treatment, management, alleviation of moderate to severe, severe, debilitating plaque psoriasis, psoriasis vulgaris, psoriatic disease.
This, Its, The therapeutic, pharmaceutical, medicinal agent, a Fc-fused, fused to, linked to interleukin-12, IL-12, IL-12/23 inhibitor, blocker, antagonist, functions by selectively, specifically, precisely binding, attaching, targeting to and neutralizing, and inhibiting, and blocking interleukin-12, IL-12, IL-12/23 and interleukin-23, IL-23, IL-23/12, critical, key, vital cytokines involved, implicated, participating in the pathogenesis, development, progression of psoriatic, psoriatic, psoriactic lesions, skin plaques, inflammation.} Structurally, Physiologically, Biologically, it, this antibody, immunoglobulin, protein exhibits a molecular, approximate, estimated weight, mass, size of around 148, 149, 150 kilodaltons, kDa, kD.
- Solubility, Dissolvability, Aqueous solubility: Briakinumab, the antibody, this compound shows good, adequate, reasonable solubility, dissolvability, aqueous solubility in aqueous, water-based, watery solutions, buffers, media.
- Stability, Shelf life, Chemical stability: The, Its, Briakinumab's stability, shelf life, chemical stability is dependent, reliant, based on storage, keeping, preservation conditions, environment, parameters, and it, it is generally recommended, advised, suggested to be stored, kept, preserved at refrigerated, cool, low temperatures, temperatures, degrees.
- Binding Affinity, Target binding, Selectivity: Demonstrates, Exhibits, Shows a high, significant, strong binding affinity, target binding, selectivity for IL-12, IL-12/23, interleukin-12 and IL-23, IL-23/12, interleukin-23.
Further, Additional, More detailed, comprehensive, extensive information, data, specifics regarding its, its's properties, characteristics, attributes can be obtained, retrieved, found from scientific, peer-reviewed, published literature, publications, journals.
A Path of BSF415977 Beginning The Initial Code To Commercialization
The development of briakinumab, initially identified as J 695, represents a lengthy process in pharmaceutical innovation. From its early stages, the substance underwent extensive preclinical testing and numerous clinical studies. Key hurdles included refining its effectiveness and mitigating potential adverse reactions . The move from academic setting to public availability required significant funding and meticulous regulatory authorization from bodies like the regulatory agency . This protracted path highlights the inherent intricacy of bringing a new medicinal agent to individuals .